This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Feb 1;3(1):3-5.

doi: 10.1161/CIRCINTERVENTIONS.110.936948.

Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"

PMID: 20160184
DOI: 10.1161/CIRCINTERVENTIONS.110.936948

Editorial

Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"

Kevin Croce. Circ Cardiovasc Interv. 2010.

. 2010 Feb 1;3(1):3-5.

doi: 10.1161/CIRCINTERVENTIONS.110.936948.

Author

PMID: 20160184
DOI: 10.1161/CIRCINTERVENTIONS.110.936948

No abstract available

PubMed Disclaimer

Comment on

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW. Jeong YH, et al. Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26. Circ Cardiovasc Interv. 2010. PMID: 20118150 Clinical Trial.

Similar articles

Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
Gurbel PA, Lau WC, Tantry US. Gurbel PA, et al. J Am Coll Cardiol. 2008 Jan 22;51(3):261-3. doi: 10.1016/j.jacc.2007.07.090. J Am Coll Cardiol. 2008. PMID: 18206733 No abstract available.
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Jeong YH, Park Y, Kim IS. Jeong YH, et al. JAMA. 2011 Jun 22;305(24):2520; author reply 2521-2. doi: 10.1001/jama.2011.842. JAMA. 2011. PMID: 21693737 No abstract available.
Clopidogrel, genetics, and drug responsiveness.
Freedman JE, Hylek EM. Freedman JE, et al. N Engl J Med. 2009 Jan 22;360(4):411-3. doi: 10.1056/NEJMe0810513. N Engl J Med. 2009. PMID: 19164193 No abstract available.
Bedside evaluation of thienopyridine antiplatelet therapy.
Price MJ. Price MJ. Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Circulation. 2009. PMID: 19451364 Review. No abstract available.
[A current problem for regulators. Clopidogrel and pharmacokinetics].
Zündorf I, Dingermann T. Zündorf I, et al. Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326. Pharm Unserer Zeit. 2009. PMID: 19572363 Review. German. No abstract available.

See all similar articles

Cited by

Aspirin plus clopidogrel versus cilostazol -based triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI: a systematic review and meta-analysis of randomized controlled trials.
Odat RM, Ahmed M, Alshwayyat S, Hussein AM, AlSaraireh TH, Molhem AM, Aldamen AO, Ababneh M, Quwaider B, Jain H, Yasin JA, Hanifa H, Ahmed R. Odat RM, et al. BMC Pharmacol Toxicol. 2025 Feb 20;26(1):36. doi: 10.1186/s40360-025-00870-x. BMC Pharmacol Toxicol. 2025. PMID: 39980074 Free PMC article.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

1K08HL086672/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information